Hikma To Join London's Blue-Chip Index as Shire Exits
20 12월 2018 - 4:25AM
Dow Jones News
By Carlo Martuscelli
Hikma Pharmaceuticals PLC (HIK.LN) will joint the FTSE 100
index, replacing Shire PLC (SHP.LN), FTSE Russell said
Wednesday.
FTSE Russell attributed the swap to Shire's takeover by Takeda
Pharmaceutical. London-listed Hikma Pharmaceuticals was founded in
Jordan, and manufactures generic medicines as well as in-licensed
products.
Shares of the company are up 65% in the past 12 months. Demand
of its injectable medicines was recently buoyed by a shortage in
the U.S., and the company reported earnings that beat analyst
expectations in its latest half-year report.
FTSE Russell said that changes to the index will be made
effective from Dec. 24.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
December 19, 2018 14:10 ET (19:10 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Hikma Pharmaceuticals plc (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Hikma Pharmaceuticals Plc. (PC) News Articles